Objective To ascertain contemporary approaches to the collection, reporting and analysis of
adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy …

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare
multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and …

Objective To present a multiyear clinical experience with intravenous bevacizumab for the
management of severe gastrointestinal bleeding and/or epistaxis in patients with hereditary …

Background Epistaxis (nosebleed) most commonly affects children and the elderly. The
majority of episodes are managed at home with simple measures. In more severe cases …

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF
receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic …

ABSTRACT Introduction: Hereditary Haemorrhagic Telangiectasia (HHT) is as an autosomal
dominant trait characterized by frequent nose bleeds, mucocutaneous telangiectases …

Correct organization of the vascular tree requires the balanced activities of several signaling
pathways that regulate tubulogenesis and vascular branching, elongation, and pruning …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …